Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients.

Boydell, Emma; Marinari, Eliana; Migliorini, Denis; Dietrich, Pierre-Yves; Patrikidou, Anna; Dutoit, Valérie.

Afiliação

Boydell E; Laboratory of Tumour Immunology and Department of Oncology, Geneva University Hospital, 1211 Geneva, Switzerland. Emma.Boydell@etu.unige.ch.
Marinari E; Translational Research Center for Oncohaematology, Department of Internal Medicine Specialties, University of Geneva, 1211 Geneva, Switzerland. Emma.Boydell@etu.unige.ch.
Migliorini D; Laboratory of Tumour Immunology and Department of Oncology, Geneva University Hospital, 1211 Geneva, Switzerland. eliana.marinari@unige.ch.
Dietrich PY; Translational Research Center for Oncohaematology, Department of Internal Medicine Specialties, University of Geneva, 1211 Geneva, Switzerland. eliana.marinari@unige.ch.
Patrikidou A; Laboratory of Tumour Immunology and Department of Oncology, Geneva University Hospital, 1211 Geneva, Switzerland. dmig@pennmedicine.upenn.edu.
Dutoit V; Translational Research Center for Oncohaematology, Department of Internal Medicine Specialties, University of Geneva, 1211 Geneva, Switzerland. dmig@pennmedicine.upenn.edu.

Cancers (Basel) ; 11(4)2019 Apr 02.

Article em En | MEDLINE | ID: mdl-30986995